Department for Therapeutic Services, Blood Transfusion Center of Slovenia, Šlajmerjeva 6, 1000 Ljubljana, Slovenia.
Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.
Int J Mol Sci. 2021 May 12;22(10):5120. doi: 10.3390/ijms22105120.
Over the years, transfusion medicine has developed into a broad, multidisciplinary field that covers different clinical patient services such as apheresis technology and the development of stem cell transplantation. Recently, the discipline has found a niche in development and production of advanced therapy medicinal products (ATMPs) for immunotherapy and regenerative medicine purposes. In clinical trials, cell-based immunotherapies have shown encouraging results in the treatment of multiple cancers and autoimmune diseases. However, there are many parameters such as safety, a high level of specificity, and long-lasting efficacy that still need to be optimized to maximize the potential of cell-based immunotherapies. Thus, only a few have gained FDA approval, while the majority of them are studied in the context of investigator-initiated trials (IITs), where modern, academically oriented transfusion centers can play an important role. In this review, we summarize existing and contemporary cellular immunotherapies, which are already a part of modern transfusion medicine or are likely to become so in the future.
多年来，输血医学已经发展成为一个广泛的多学科领域，涵盖了不同的临床患者服务，如单采技术和干细胞移植。最近，该学科在为免疫治疗和再生医学目的开发和生产先进治疗性药物产品（ATMP）方面找到了一个利基。在临床试验中，基于细胞的免疫疗法在治疗多种癌症和自身免疫性疾病方面显示出令人鼓舞的结果。然而，仍然有许多参数需要优化，如安全性、高水平的特异性和持久的疗效，以最大限度地发挥基于细胞的免疫疗法的潜力。因此，只有少数获得了 FDA 的批准，而大多数都在研究者发起的试验（IIT）中进行研究，现代的、以学术为导向的输血中心可以在其中发挥重要作用。在这篇综述中，我们总结了现有的和当代的细胞免疫疗法，它们已经是现代输血医学的一部分，或者将来可能成为其中的一部分。
